“…S768I is an uncommon mutation and accounts for 1.5 %–3 % of untreated EGFR-mutated tumours [ 24 , 25 ]. Patients harbouring S768I exhibit good TKI treatment responses and prognosis [ 26 ]. Multiple studies have shown that afatinib is effective for NSCLC patients with the S768I mutation [ 27 ].…”